http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Gamida Cell (GMDA) Presents Updated Omidubicel Data
-
Gamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
-
Gamida Cell Ltd. (GMDA) Announces Results of New Health Economic and Outcome Study Reporting Improved Health Equity and Health Outcomes With Omidubicel at 2022 Transplantation & Cellular Therapy Meeti
-
Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health Equity and Health Outcomes With Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of A
-
Gamida Cell to Present Corporate Highlights and Participate in Panel Discussion at the Needham Healthcare Conference
-
Gamida Cell Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
-
Gamida Cell to Present Corporate Highlights at the Oppenheimer 32nd Annual Healthcare Conference
-
Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results and Webcast
-
Gamida Cell Ltd. (GMDA) Initiates Rolling Submission of Biologics License Application for Omidubicel
-
Gamida Cell Initiates Rolling Submission of Biologics License Application for Omidubicel
-
Gamida Cell Ltd. (GMDA) Appoints Anat Cohen-Dayag and Naama Halevi-Davidov to its Board
-
Gamida Cell Announces Appointment of Anat Cohen-Dayag and Naama Halevi-Davidov to its Board of Directors
-
Gamida Cell (GMDA) Initiates Rolling BLA Submission for omidubicel, Announces Updates and 2022 Financial Guidance
-
Gamida Cell Provides Key Program Updates and 2022 Financial Guidance
-
Gamida Cell (GMDA) receives positive Type B meeting correspondence from FDA on Omidubicel BLA submission
-
Gamida Cell Provides Update on Omidubicel BLA Submission
-
Gamida Cell Announces Data to be Presented at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
-
Gamida Cell Presents Two-Year Survival Data for GDA-201 and Resource Utilization Analysis for Omidubicel at 63rd ASH Annual Meeting
-
Gamida Cell Presents New Omidubicel Data at 63rd ASH Annual Meeting
-
Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences
-
Gamida Cell Reports Third Quarter 2021 Financial Results and Provides Company Update
-
Gamida Cell (GMDA) Provides Update on Pre-BLA Meeting With FDA for Omidubicel, FDA Requested Revised Analysis of Manufacturing Data
-
Gamida Cell Provides Update on Pre-BLA Meeting With FDA for Omidubicel
-
Gamida Cell Presents New Data on Nicotinamide-Enabled NK Cell Therapy at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
-
Gamida Cell Announces the Date of Its Third Quarter 2021 Financial Results and Webcast
-
Gamida Cell Announces Data to Be Presented at 63rd ASH Annual Meeting
-
Gamida Cell Presents Data on its NAM-Enabled NK Cell Therapies at Protein & Antibody Engineering Summit (PEGS) Europe
-
Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today’s Virtual R&D Day
-
Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
-
Gamida Cell to Host Virtual Event Highlighting GDA-201 and NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline
-
Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in September
-
Gamida Cell Reports Second Quarter 2021 Financial Results and Provides Company Update
-
Gamida Cell Announces the Date of Its Second Quarter 2021 Financial Results and Webcast
-
Gamida Cell to Present at the BTIG Virtual Biotechnology Conference
-
Gamida Cell (GMDA) Announces Publication in Blood of First Pivotal Trial to Evaluate a Cell Therapy for Patients with Blood Cancer who Require Allogeneic Stem Cell Transplant
-
Gamida Cell Announces Publication in Blood, the Journal of the American Society of Hematology, of the First Pivotal Trial to Evaluate a Cell Therapy (Omidubicel) for Patients with Blood Cancer who Req
-
Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in June
-
Gamida Cell Announces Appointment of Senior Vice President, Global Operations and Manufacturing and Provides Commercial Manufacturing Update
-
Gamida Cell to Present at the RBC Capital Markets Global Healthcare Conference
-
Gamida Cell Reports First Quarter 2021 Financial Results and Provides Company Update
-
Gamida Cell Announces the Date of Its First Quarter 2021 Financial Results and Webcast
-
Gamida Cell to Present at the 20th Annual Needham Virtual Healthcare Conference
-
Gamida Cell Ltd. (GMDA) Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at EBMT
-
Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 47th Annual Meeting of the European Society for Blood and Marrow Transp
-
Gamida Cell Reports Full Year 2020 Financial Results and Provides Company Update
-
Gamida Cell to Present at Upcoming Investor Conferences
-
Gamida Cell Announces the Date of Its Full Year 2020 Financial Results and Webcast
-
Gamida Cell Ltd. (GMDA) Announces Results from Phase 3 Study of Omidubicel to be Presented at EBMT
-
Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
-
Gamida Cell Announces $75 Million Financing with Highbridge Capital Management
